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Society of Cardiology responded to the on – line questionnaire. The majority of
respondents agree that medical devices and equipment are not adequately regu-
lated at the moment in Turkey. Moreover they believe that manufacturing compa-
nies have too much influence on how medical devices and equipment are regu-
lated. The majority of the cardiologists value recommendations from colleagues.
When making risk/benefit decisions, surgeons rely on sharing information about
the merits and drawbacks of particular devices within their local peer groups,
especially Turkish Society of Cardiology, rather than using more formal avenues.
Cardiologists would be most likely to turn to the risk assessment unit at the hos-
pital they work for. Then they woul like to report the adverse events to the Ministry
of Health of Turkey General Directorate of Pharmaceuticals and Pharmacy, which
is the main regulating institution in Turkey. CONCLUSIONS: The qualitative anal-
ysis results indicate that efforts should be directed to inform cardiologists about
the functioning of General Directorate of Pharmaceuticals and Pharmacy and the
guidelines of medical device regulations.
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OBJECTIVES: Clinical trial publications commonly report only adverse event (AE)
rates occurring above an arbitrary threshold. Our objective was to devise a meta-
analysis technique that allowed trials to be included even when AE rates fell below
thresholds. METHODS: A maximum likelihood simulation (MLS) was devised that
assumed all AE trial results lay in the same binomial distribution truncated by
reporting thresholds. AE data from osteoarthritis trials were retrieved. The MLS
was executed using the random number generator and binomial distribution func-
tion of CafeSim, a Java modeling toolkit. Ten million iterations, needed for conver-
gence, were run for each tenth of a percent up to the highest rate reported. For each
iteration the values generated from the binomial function were compared to the
published AE rates and/or thresholds. The rate with the most matches was desig-
nated the point estimate (PE). The range from the 2.5 to 97.5 percentiles of matches
was the 95% confidence interval (CI). Verification was conducted for 2 AEs of 2
compounds. Results for 2 AEs reported in all etoricoxib trials were compared to
Comprehensive Meta-Analysis (CMA) results. Results for 2 AEs below reporting
thresholds of one or more diclofenac trials were compared to results from equiva-
lent SAS code using RANBIN and PROC FREQ. RESULTS: The MLS estimated PEs and
CIs for the etoricoxib AEs within 0.001 of CMA (hypertension PE  0.058 (0.059 for
MLS), CI [0.051, 0.065]). The MLS executed in CafeSim estimated PEs and CIs for the
diclofenac AEs within 0.002 of those estimated in SAS, identical for hypertension,
(PE  0.027, CI [0.022, 0.032]). When trials reported widely differing rates the MLS
converged slowly. The MLS estimated 0.000 when no trials reported the AE rate.
CONCLUSIONS:An MLS technique assuming a common binomial distribution may
provide a useful estimate of AE rates when they occasionally fall below reporting
thresholds.
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INTRODUCTION: An Excel calculator tool was created to perform meta-analysis in
a rapid manner. The tool performs both direct and indirect treatment comparisons.
A recent meta-analysis study examining rheumatoid arthritis (RA) was replicated
using the calculator. OBJECTIVES: To quickly perform meta-analyses, both direct
and indirect treatment comparisons, using Microsoft Excel. METHODS: We used a
random effects DerSimonian and Laird model by inputting the number of studies
and binary outcomes variables to report the Relative Risk (RR) for each study and a
pooled overall RR. The Q-statistic and the I-squared statistic were used to examine
heterogeneities across studies. Indirect treatment comparisons between specific
studies were performed post hoc. Indirect pair-wise comparisons were also per-
formed between studies. RESULTS: Three studies (Lipsky, Keystone, and Klares-
kog) were examined, comparing a combination of tumor necrosis factor (TNF) in-
hibitors plus methotrexate (MTX) to MTX monotherapy. Each study was evaluated
using the number of patients achieving American College of Rheumatology (ACR)
scores 20, 50, and 70. To test the Excel calculator, the number of patients obtaining
ACR20 scores was used in the replication. The overall RR was 1.89 (95% CI: 0.89,
4.00), which was not statistically significant (p-value0.10). There were significant
heterogeneities across treatments and the I-squared statistic was 96.2% (p-
value0.000). The Lipsky and Keystone studies had statistically significant treat-
ment effects relative to the Klareskog trial: Lipsky vs. Klareskog: RR 2.23 (95% CI:
1.37, 3.64, p-value0.001); Keystone vs. Klareskog: RR 2.17 (95% CI: 1.63, 2.89,
p-value0.001).CONCLUSIONS: The meta-analysis Excel calculator is a simple and
quick way to run random effect models with binary data. The replication output
matched the results of the original paper.
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OBJECTIVES: To compare indirect and MTC meta-analysis techniques used in the
evaluation of the protease inhibitors, boceprevir and telaprevir, in combination
with peginterferon alfa and ribavirin for the treatment of patients with genotype 1
chronic Hepatitis C. METHODS: A systematic search of the literature was con-
ducted in EMBASE and MEDLINE (January 2008 to May 2012) to identify studies that
utilised either indirect or MTC meta-analysis techniques to derive the relative
treatment effect between boceprevir and telaprevir. A qualitative comparison was
made between the methodologies and results of the identified studies. RESULTS:
Two publications were identified: a conference poster (Diels et al.) and a full publi-
cation (Cooper et al.). The main difference between the methodologies is that Coo-
per et al. used an adjusted indirect comparison and a random-effects MTC model
whereas Diels et al. used a fixed-effects MTC model. Diels et al. included three
further studies that compare peginterferon alfa-2a and alfa-2b without active ther-
apies. Cooper et al. conducted a random-effects adjusted indirect comparison that
included two additional telaprevir trials that were excluded from Diels et al. The
primary outcome in both studies was the proportion of patients achieving sus-
tained virologic response. Diels et al. reported no significant difference in treatment
naive patients and a significant effect in favour of telaprevir for treatment experi-
enced patients. When Diels et al. applied a random-effects model the effect of
telaprevir being superior in treatment experienced patients was non-significant.
The results reported by Cooper et al. showed no significant difference between
boceprevir and telaprevir, and did not vary in sensitivity analyses. CONCLUSIONS:
Comparison of these two studies highlights considerable methodological differ-
ences between the two approaches, which result in differing conclusions. While
MTC methods are growing in popularity and importance, certain nuances of ap-
proaches can result in important differences in interpretation.
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OBJECTIVES: To extend well-established methods for sample size in power calcu-
lations in pair wise meta-analysis to the scenario where multiple treatments are
being analyzed in a network meta-analysis METHODS: We derive methods of ap-
proximating the ‘effective number of patients’ in indirect comparison meta-anal-
ysis where no head-to-head evidence is available. We calibrate these approaches
with conventional approaches for estimating the required sample size and power
in pair wise meta-analysis. RESULTS: The calibration of the above two methods
allow for a simple assessment of the power and strength of evidence for each
treatment comparison in a network of treatments. The resulting measures are 1)
the statistical power associated with each treatment comparison made in a net-
work meta-analysis; 2) the effective number of patients for each comparison con-
trasted, which can be contrasted with the required sample size for the particular
comparison to gauge the strength of evidence. We provide an illustrative example
using data from a network meta-analysis of interventions for smoking cessation.
CONCLUSIONS: The proposed measured follow the format of well-known sample
size and power measures. They are easy to calculate and will resonate with a
statistically non-sophisticated audience.
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OBJECTIVES: This research uses a comparative analysis framework between na-
tional health care systems and continues the theoretical development of the 3P
theory. It demonstrates that sets of cost reduction strategies and by physicians,
Pharmacists and Patients as well as different meanings of cost (cost the system,
cost to the physician, and cost to the patient) choices per group of physicians lead
to very different decision points in each system and variations in sets of clinical
choices for similar patients. A random utility model is proposed. METHODS: Data
are extracted from the endep/biomed database for 600 physicians, transcripts from
qualitative focus groups and estimates from the centralized database of 6 patients’
surveys on cost of medicines (www.endeplux.org). The thinking about cost is clas-
sified in Cost S (cost to the System), Cost Ph (cost to the Physician) Cost Pa (cost to
the Patient).The conceptual framework has been mainly developed from pair of
country comparisons, especially from the French, German and Italian physicians
analysis (Huttin, Andral; 2003; Atella et als; 2003; Brenner et als, 2002). RESULTS: A
comparative intercountry framework is used to weight differently combinations of
(Cost S, Cost Ph, Cost Pa) in the system. A generalization will be proposed with a list
of different possible combinations aCostSbCostPhCostPa for each physician ij
among N physicians in J Health financing systems. CONCLUSIONS: This research
step aims to propose a link between a research line on transaction cost politics and
several statistical developments for a stated revealed preference disease econo-
metric model. It will help to identify the type of random utility models that would
clearly model how variations of preferences from Physicians, Pharmacist, Patients
that could help to manage variations between different national health care fi-
nancing systems.
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OBJECTIVES: To uses Latent Transition Analysis (LTA) to assess the difference in
the change in severity of a Neurological disorder between patients in two treat-
ment groups. The patients in the study were assigned to one of two treatment
groups Active or Placebo over a period of 6 months and the results to a question-
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